Cargando…

Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience

Immune checkpoint inhibitors (ICIs), pembrolizumab in particular, have been shown to be vastly more efficacious than traditional cytotoxic or platinum-based chemotherapies in the treatment of non-small cell lung cancer (NSCLC). While there are plenty of data showing their efficacy and safety profile...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shalata, Walid, Zolnoorian, Jeremy, Migliozzi, Gabrielle, Jama, Ashraf Abu, Dudnik, Yulia, Cohen, Ahron Yehonatan, Meirovitz, Amichay, Yakobson, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056863/ https://www.ncbi.nlm.nih.gov/pubmed/36983011 http://dx.doi.org/10.3390/ijms24065938

Ejemplares similares

Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer
por: Shalata, Walid, et al.
Publicado: (2023)

Dermatomyositis Associated with Lung Cancer: A Brief Review of the Current Literature and Retrospective Single Institution Experience
por: Shalata, Walid, et al.
Publicado: (2022)

Cemiplimab as First Line Therapy in Advanced Penile Squamous Cell Carcinoma: A Real-World Experience
por: Rouvinov, Keren, et al.
Publicado: (2023)

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma
por: Shalata, Walid, et al.
Publicado: (2023)

Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma)
por: Shalata, Walid, et al.
Publicado: (2021)

Radiotherapy-Induced Atrial Myxoma: A Case Report and Literature Review
por: Shalata, Walid, et al.
Publicado: (2023)

Unexpected Adverse Events of Immune Checkpoint Inhibitors
por: Shalata, Walid, et al.
Publicado: (2023)

Tolerated Re-Challenge of Immunotherapy in a Patient with ICI Associated Myocarditis: A Case Report and Literature Review
por: Shalata, Walid, et al.
Publicado: (2023)

PD-1 Inhibitors in Elderly and Immunocompromised Patients with Advanced or Metastatic Cutaneous Squamous Cell Carcinoma
por: Yakobson, Alexander, et al.
Publicado: (2023)

Carpal Tunnel Syndrome Associated with Immune Checkpoint Inhibitors
por: Yakobson, Alexander, et al.
Publicado: (2023)

Is Elevation of Alkaline Phosphatase a Predictive Factor of Response to Alectinib in NSCLC?
por: Shalata, Walid, et al.
Publicado: (2021)

Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis
por: Rouvinov, Keren, et al.
Publicado: (2023)

Unexpected and Rare Sites of Metastasis in Oncologic Patients
por: Shalata, Walid, et al.
Publicado: (2023)

A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors
por: Shalata, Walid, et al.
Publicado: (2022)

Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer
por: Kian, Waleed, et al.
Publicado: (2022)

Associated Myocarditis: A Predictive Factor for Response?
por: Shalata, Walid, et al.
Publicado: (2020)

Bullous Pemphigoid Occurring after Stopping Imatinib Therapy of CML: Is a Continuation of Post-Treatment Follow-Up Needed?
por: Yakobson, Alexander, et al.
Publicado: (2023)

Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future
por: Szeto, Chun Ho, et al.
Publicado: (2021)

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review
por: Shalata, Walid, et al.
Publicado: (2021)

Epithelioid Hemangioendothelioma and Epithelioid Hemangioma: Pazopanib as a Potential Salvage Therapy
por: Yakobson, Alexander, et al.
Publicado: (2021)

Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
por: Chen, Yen-Hao, et al.
Publicado: (2023)

A Rare Case of Cutaneous Metastasis of Bladder Transitional Cell Carcinoma
por: Fachler, Tahel, et al.
Publicado: (2021)

Real-world experience with pembrolizumab in patients with advanced soft tissue sarcoma
por: Liu, Jiayong, et al.
Publicado: (2021)

Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors
por: Hurkmans, Daan P., et al.
Publicado: (2021)

Endovascular brachytherapy for extensive right-heart and pulmonary artery sarcoma – a case report
por: Aviel, Gal, et al.
Publicado: (2019)

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data
por: Dudnik, Elizabeth, et al.
Publicado: (2021)

Reducing the number of CTs performed to monitor personalized dosimetry during peptide receptor radionuclide therapy (PRRT)
por: Chicheportiche, Alexandre, et al.
Publicado: (2018)

Programmed death-ligand 1 expression discrepancy between primary tumor and metastatic lymph nodes in non-small cell lung cancer
por: Kian, Waleed, et al.
Publicado: (2020)

Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies
por: Choi, Min Chul, et al.
Publicado: (2020)

Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population
por: Ahmadzada, Tamkin, et al.
Publicado: (2020)

A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC
por: Fujimoto, Daichi, et al.
Publicado: (2021)

Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
por: Kuo, Hsin-Yu, et al.
Publicado: (2022)

Metabolic Activity Assessment by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients after COVID-19 Vaccination
por: Shalata, Walid, et al.
Publicado: (2022)

Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management
por: Chicheportiche, Alexandre, et al.
Publicado: (2020)

Induction of heparanase by HPV E6 oncogene in head and neck squamous cell carcinoma
por: Hirshoren, Nir, et al.
Publicado: (2014)

Radiation-Induced Nephropathy in the Murine Model Is Ameliorated by Targeting Heparanase
por: Abecassis, Alexia, et al.
Publicado: (2023)

Predictive power of the post-treatment scans after the initial or first two courses of [(177)Lu]-DOTA-TATE
por: Chicheportiche, Alexandre, et al.
Publicado: (2018)

Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations
por: Janzic, Urska, et al.
Publicado: (2023)

Real-world experience with pembrolizumab in patients with advanced melanoma: A large retrospective observational study
por: Liu, Frank Xiaoqing, et al.
Publicado: (2019)

Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience
por: Purim, Ofer, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7b30i1g48rfjf3drprcrmbn6se